WuXi Biologics’ subsidiary, WuXi Vaccines, is investing $240 million to build a new vaccine manufacturing facility in Ireland. This investment follows the 20-year manufacturing Letter of Intent (LOI) signed by WuXi Vaccines earlier this year. Under the LOI, this new dedicated vaccine manufacturing facility, including drug substance manufacturing (MFG15), drug product manufacturing (DP5) as well as Quality Control labs (QC), will supply a vaccine product of a large global pharma for the global...